In Oncology there are many drugs in development and many drugs has been approved for the treatment of cancer. There are small molecules, biologic drugs, vaccine, gene therapies, Immunotherapies which are in development for cancer disease. But the development of novel targeted therapies for cancer treatment with acceptable safety is critical. Immunotherapy offers promising opportunities with the potential to induce sustained remissions in patients with refractory disease. In Immunotherapies adoptive cell transfer (ACT) approach is rapidly emerging approach. ACT are of several types including Tumor-infiltrating lymphocytes (TILs), T Cell Receptors (TCR) and Chimeric antigen receptors T (CAR-T) cells. CAR-T cells are advanced development for treating cancer. In research CAR-T cells therapy open a new door for treatment of cancer disease. CAR-T cells are consisting of extracellular single-chain variable fragment (scFv), transmembrane domain, and intracellular part of immunoreceptor tyrosine-based activation motifs (ITAMs). CAR-T cells have shown good response in clinical trials for B-cell malignancies. CAR-T cells therapies are engineered from patients own immune cells and infused back into the patients.

Development in CAR-T cells therapy have been seen from first generation CAR-T cells to fourth generation CAR-T cells and continuously getting advanced. There different types of CAR-T cells which includes TRUCK Car, Universal Car, Self-driving CAR, Armored CAR, Self-destruct CAR, Conditional CAR, Marked CAR, TanCAR, Dual CAR and sCAR.

Two CAR-T cells have been approved namely Yescarta and Kymriah. Yescarta is approved for the treatment of Diffuse Large B-cell lymphoma (DLBCL) and Kymriah is approved for the treatment of Acute lymphoblastic leukemia (ALL) and Diffuse Large B-Cell Lymphoma (DLBCL) by the USFDA and EMA. Pipeline Analysis showed that the 50% of CAR-T are in development for Liquid tumor and 37% of CAR-T cells therapy for Solid tumor. 2% of CAR-T is for Solid tumor and liquid tumor both. 10% of CAR-T cells therapy are in development for Unknown cancer i.e. the companies had not disclosed the cancer types.

Companies as Novartis, Gilead, Johnson and Johnson, Amgen, Takeda, GlaxoSmithKline, Intellia Therapeutics, Pfizer, Roche and many more are in race for the development of CAR-T cells. Companies are collaborating for the development and research for CAR-T cells therapy with other companies, research institutes and hospitals.

CAR-T cell therapy pipeline report includes the CAR-T cells therapy, which are in development in Phase I, Phase II, Phase III, Preclinical, Discovery and Unknown Phase. The report also includes the detailed description of Marketed and Phase III CAR-T cells therapies. In this report Major Collaboration and Partnership for CAR-T cells therapy also described.

Key Questions Answered:

Working of CAR-T cells therapy
Progression in CAR-T cells therapy research
Types of CAR-T cells therapy
Detailed description of Approved CAR-T cells therapy
Target included in CAR-T cells therapy
Pipeline of CAR-T cells therapy
Phase I CAR-T cells
Phase II CAR-T cells
Phase III CAR-T cells
Detailed description of Phase III Car-T cells therapy
Preclinical CAR-T cells therapy
Discovery Phase CAR-T cells therapy
Unknown Phase CAR-T cells therapy
Major Collaboration/Partnership
Pipeline Analysis by Indication in different Phase of development

1. Executive Summary

2. Key Question Answered

3. CAR-T Introduction

I. Monoclonal antibodies (MABs)

II. Checkpoint Inhibitors

III. Cytokines

IV. Vaccines

V. Adoptive Cell transfer (ACT)

VI. CAR-T Cell Therapy

a. Structure of CAR-T Cells

VII. Work Process of CAR-T Cell therapy

VIII. Progression in CAR-T cells research

a. First Generation CAR-T cells

b. Second Generation CAR-T cells

c. Third generation

d. Fourth generation

IX. Types of CAR-T Cells

a. TRUCK CAR

b. Universal CAR

c. Self-driving CAR

d. Conditional CAR

e. Marked CAR

f. TanCAR

g. Dual CAR

h. sCAR

X. Approved CAR-T cell therapy

a. Yescarta (axicabtagene ciloleucel, KTE-C19, KTE-X19)

i. Pivotal Study of Yescarta

ii. Phase III Study of Yescarta

iii. Phase II Study of Yescarta

iv. Phase I/II Study of Yescarta

v. Phase I/II Combination Study of axicabtagene ciloleucel with Atezolizumab

vi. Phase I/II Combination Study of axicabtagene ciloleucel with Utomilumab

vii. Expanded Access Study of Yescarta

b. Kymriah (tisagenlecleucel)

i. Pivotal Study of Kymriah for Acute lymphoblastic leukemia (ALL)

ii. Pivotal Study of Kymriah for Diffuse Large B-Cell Lymphoma (DLBCL)

iii. Phase III study of Kymriah

iv. Phase I Combination study of Kymriah

c. Targets of CAR-T cell therapy

i. Target Introduction

4. Pipeline of CAR-T cell therapy

I. Pipeline Analysis by Phase of Molecule

a. Phase I Molecules

b. Phase II Molecules

c. Phase III Molecules

i. bb2121 (BCMA CAR-T)

ii. Collaboration

c.ii.i. Phase I study of bb2121

c.ii.ii. Phase II studies of bb2121

c.ii.iii. Phase III study of bb2121

iii. lisocabtagene maraleucel (JCAR017; liso-cel)

c.iii.i. Phase III study of lisocabtagene maraleucel

c.iii.ii. Phase II study of lisocabtagene maraleucel

c.iii.iii. Phase I Study of lisocabtagene maraleucel

5. Preclinical Molecules

6. Discovery Phase Molecules

7. Unknown Phase Molecules

8. Pipeline Analysis by Indication

9. Major Collaboration/Partnership for CAR-T cells developments

I. Acquisitions

10. About EffeMarket

11. Disclaimer

12. Contact US

Figure 1: Structure of CAR-T cells

Figure 2: Work Process of CAR-T Cell therapy

Figure 3:Progression in CAR-T cells therapy research

Figure 4: Number of Molecules in Different Phase of development

Figure 5: Pipeline Analysis by Indication

Figure 6: Pipeline Analysis by Phase III

Figure 7: Pipeline Analysis by Phase II

Figure 8: Pipeline Analysis by Phase I

Figure 9: Pipeline Analysis by Preclinical Phase

Figure 10: Pipeline Analysis by Phase Unknown

Figure 11: Pipeline Analysis by Discovery Phase

Table 1: CAR-T Therapy Targets

Table 2: Phase I Molecules (1/45)

Table 3: Phase I Molecules (2/45)

Table 4: Phase I Molecules (3/45)

Table 5: Phase I Molecules (4/45)

Table 6: Phase I Molecules (5/45)

Table 7: Phase I Molecules (6/45)

Table 8: Phase I Molecules (7/45)

Table 9: Phase I Molecules (8/45)

Table 10: Phase I Molecules (9/45)

Table 11: Phase I Molecules (10/45)

Table 12: Phase I Molecules (11/45)

Table 13: Phase I Molecules (12/45)

Table 14: Phase I Molecules (13/45)

Table 15: Phase I Molecules (14/45)

Table 16: Phase I Molecules (15/45)

Table 17: Phase I Molecules (16/45)

Table 18: Phase I Molecules (17/45)

Table 19: Phase I Molecules (18/45)

Table 20: Phase I Molecules (19/45)

Table 21: Phase I Molecules (20/45)

Table 22: Phase I Molecules (21/45)

Table 23: Phase I Molecules (22/45)

Table 24: Phase I Molecules (23/45)

Table 25: Phase I Molecules (24/45)

Table 26: Phase I Molecules (25/45)

Table 27: Phase I Molecules (26/45)

Table 28: Phase I Molecules (27/45)

Table 29: Phase I Molecules (28/45)

Table 30: Phase I Molecules (29/45)

Table 31: Phase I Molecules (30/45)

Table 32: Phase I Molecules (31/45)

Table 33: Phase I Molecules (32/45)

Table 34: Phase I Molecules (33/45)

Table 35: Phase I Molecules (34/45)

Table 36: Phase I Molecules (35/45)

Table 37: Phase I Molecules (36/45)

Table 38: Phase I Molecules (37/45)

Table 39: Phase I Molecules (38/45)

Table 40: Phase I Molecules (39/45)

Table 41: Phase I Molecules (40/45)

Table 42: Phase I Molecules (41/45)

Table 43: Phase I Molecules (42/45)

Table 44: Phase I Molecules (43/45)

Table 45: Phase I Molecules (44/45)

Table 46: Phase I Molecules (45/45)

Table 47:Phase II Molecules (1/2)

Table 48:Phase II Molecules (2/2)

Table 49: Phase III Molecules

Table 50: Preclinical Molecules (1/30)

Table 51: Preclinical Molecules (2/30)

Table 52: Preclinical Molecules (3/30)

Table 53: Preclinical Molecules (4/30)

Table 54: Preclinical Molecules (5/30)

Table 55: Preclinical Molecules (6/30)

Table 56: Preclinical Molecules (7/30)

Table 57: Preclinical Molecules (8/30)

Table 58: Preclinical Molecules (9/30)

Table 59: Preclinical Molecules (10/30)

Table 60: Preclinical Molecules (11/30)

Table 61: Preclinical Molecules (12/30)

Table 62: Preclinical Molecules (13/30)

Table 63: Preclinical Molecules (14/30)

Table 64: Preclinical Molecules (15/30)

Table 65: Preclinical Molecules (16/30)

Table 66: Preclinical Molecules (17/30)

Table 67: Preclinical Molecules (18/30)

Table 68: Preclinical Molecules (19/30)

Table 69: Preclinical Molecules (20/30)

Table 70: Preclinical Molecules (21/30)

Table 71: Preclinical Molecules (22/30)

Table 72: Preclinical Molecules (23/30)

Table 73: Preclinical Molecules (24/30)

Table 74: Preclinical Molecules (25/30)

Table 75: Preclinical Molecules (26/30)

Table 76: Preclinical Molecules (27/30)

Table 77: Preclinical Molecules (28/30)

Table 78: Preclinical Molecules (29/30)

Table 79: Preclinical Molecules (30/30)

Table 80: Discovery Phase Molecules(1/6)

Table 81: Discovery Phase Molecules (2/6)

Table 82: Discovery Phase Molecules (3/6)

Table 83: Discovery Phase Molecules (4/6)

Table 84: Discovery Phase Molecules (5/6)

Table 85: Discovery Phase Molecules (6/6)

Table 86: Unknown Phase Molecules (1/2)

Table 87: Unknown Phase Molecules (2/2)

Global CAR-T Pipeline Analysis Report in Oncology: 2018

License Type

Related Reports

Global Electroceuticals Market Report: 2025

Global 3D Bio-printing Market Report: 2025

Global Smart Inhalers Market Report: 2025

Global Acne Market Report: 2027

Global Cystic Fibrosis Market Report: 2028

Global AI in Healthcare Market Report: 2027

Renal Cell Carcinoma Pipeline Analysis Report: 2017

Indian Acne Market Report: 2025

Virtual Reality in Healthcare Report: 2026

Global Anti-Aging Market Report: 2026

Cystic Fibrosis Pipeline Analysis Report

Global Psoriasis Market Report: 2027

Global Renal Cell Carcinoma Market Report: 2028

AI in Medical Imaging Market Report: 2027

Global Smart Pills Market Report: 2026

Global EPDM Market Report: 2027

Global Connected Fertility Market Report: 2028

Global Dermatology Market Report: 2026

Gaucher Disease Market Report: 2026

Global Gene Therapy Market Report: 2026

Global Biofuel Market Report: 2026

Global CML Market Report: 2022

Global Lupus Nephritis Market Report: 2026

Global Molecular Diagnostics Market Report: 2026

Global Stents Market Report: 2026

Nonalcoholic Fatty Liver Disease (NASH) Market Report: 2024

Global Blockchain in Healthcare Report: 2019

Global CAR-T Pipeline Analysis Report in Oncology: 2018

Global Electric Vehicles Report: 2026

Global Connected Fertility Market Report: 2028

Global Dermatology Market Report: 2026

$3499 Get Free 10% Customization
License Type Single License Corporate License
Add to Cart Download Brochure